178 related articles for article (PubMed ID: 17136334)
1. Standard interferon-alpha in combination with ribavirin for hepatitis C patients with advanced liver disease and thrombocytopenia.
Hofer H; Gurguta C; Bergholz U; Steindl-Munda P; Ferenci P
Wien Klin Wochenschr; 2006 Oct; 118(19-20):595-600. PubMed ID: 17136334
[TBL] [Abstract][Full Text] [Related]
2. Pegylated interferon-alpha2b plus ribavirin: an efficacious and well-tolerated treatment regimen for patients with hepatitis C virus related histologically proven cirrhosis.
Roffi L; Colloredo G; Pioltelli P; Bellati G; Pozzpi M; Parravicini P; Bellia V; Del Poggio P; Fornaciari G; Ceriani R; Ramella G; Corradi C; Rossini A; Bruno S;
Antivir Ther; 2008; 13(5):663-73. PubMed ID: 18771050
[TBL] [Abstract][Full Text] [Related]
3. Eltrombopag increases platelet numbers in thrombocytopenic patients with HCV infection and cirrhosis, allowing for effective antiviral therapy.
Afdhal NH; Dusheiko GM; Giannini EG; Chen PJ; Han KH; Mohsin A; Rodriguez-Torres M; Rugina S; Bakulin I; Lawitz E; Shiffman ML; Tayyab GU; Poordad F; Kamel YM; Brainsky A; Geib J; Vasey SY; Patwardhan R; Campbell FM; Theodore D
Gastroenterology; 2014 Feb; 146(2):442-52.e1. PubMed ID: 24126097
[TBL] [Abstract][Full Text] [Related]
4. A review of the treatment of chronic hepatitis C virus infection in cirrhosis.
Vezali E; Aghemo A; Colombo M
Clin Ther; 2010 Dec; 32(13):2117-38. PubMed ID: 21316532
[TBL] [Abstract][Full Text] [Related]
5. Low-Dose Pegylated Interferon α-2b Plus Ribavirin for Elderly and/or Cirrhotic Patients with Genotype 2 Hepatitis C Virus.
Tamai H; Shingaki N; Mori Y; Moribata K; Kawashima A; Maeda Y; Niwa T; Deguchi H; Inoue I; Maekita T; Iguchi M; Kato J; Ichinose M
Gut Liver; 2016 Jul; 10(4):617-23. PubMed ID: 26601828
[TBL] [Abstract][Full Text] [Related]
6. Treatment of recurrent hepatitis C after liver transplantation: a pilot study of peginterferon alfa-2b and ribavirin combination.
Dumortier J; Scoazec JY; Chevallier P; Boillot O
J Hepatol; 2004 Apr; 40(4):669-74. PubMed ID: 15030984
[TBL] [Abstract][Full Text] [Related]
7. Pegylated interferon alpha-2a and ribavirin combination therapy in HCV liver transplant recipients. Experience of 7 cases.
Iacob S; Gheorghe L; Hrehoret D; Becheanu G; Herlea V; Popescu I
J Gastrointestin Liver Dis; 2008 Jun; 17(2):165-72. PubMed ID: 18568137
[TBL] [Abstract][Full Text] [Related]
8. Short duration treatment in genotype 1 chronic hepatitis C patients with rapid virologic response to pegylated interferon plus ribavirin.
Bonardi R; Tabone M; Manca A; Pellicano R; Ciancio A; Rizzetto M
Biomed Pharmacother; 2011 Jul; 65(4):303-6. PubMed ID: 21723079
[TBL] [Abstract][Full Text] [Related]
9. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial.
Manns M; Marcellin P; Poordad F; de Araujo ES; Buti M; Horsmans Y; Janczewska E; Villamil F; Scott J; Peeters M; Lenz O; Ouwerkerk-Mahadevan S; De La Rosa G; Kalmeijer R; Sinha R; Beumont-Mauviel M
Lancet; 2014 Aug; 384(9941):414-26. PubMed ID: 24907224
[TBL] [Abstract][Full Text] [Related]
10. Telaprevir can be successfully and safely used to treat older patients with genotype 1b chronic hepatitis C.
Furusyo N; Ogawa E; Nakamuta M; Kajiwara E; Nomura H; Dohmen K; Takahashi K; Satoh T; Azuma K; Kawano A; Tanabe Y; Kotoh K; Shimoda S; Hayashi J;
J Hepatol; 2013 Aug; 59(2):205-12. PubMed ID: 23542346
[TBL] [Abstract][Full Text] [Related]
11. Extended duration therapy with pegylated interferon and ribavirin for patients with genotype 3 hepatitis C and advanced fibrosis: final results from the STEPS trial.
Shoeb D; Dearden J; Weatherall A; Bargery C; Moreea S; Alam S; White E; Vila X; Freshwater D; Ryder S; Mills PR; Alexander GJ; Forton D; Foster GR
J Hepatol; 2014 Apr; 60(4):699-705. PubMed ID: 24291239
[TBL] [Abstract][Full Text] [Related]
12. Daily or three times per week interferon alpha-2b in combination with ribavirin or interferon alone for the treatment of patients with chronic hepatitis C not responding to previous interferon alone.
de Lédinghen V; Trimoulet P; Winnock M; Bernard PH; Bourlière M; Portal I; Rémy AJ; Szostak N; Lévy S; Tran A; Abergel A; Chêne G; Fleury H; Couzigou P;
J Hepatol; 2002 Jun; 36(6):819-26. PubMed ID: 12044534
[TBL] [Abstract][Full Text] [Related]
13. Combination therapy of low-dose of PegIFNa-2a and ribavirin for patients with HCV-infected decompensated cirrhosis.
Sun Y; Chang B; Teng G; Zhang W; Zhao J; Li B
Hepatogastroenterology; 2013 Sep; 60(126):1391-8. PubMed ID: 23635509
[TBL] [Abstract][Full Text] [Related]
14. A randomized trial of 24- vs. 48-week courses of PEG interferon alpha-2b plus ribavirin for genotype-1b-infected chronic hepatitis C patients: a pilot study in Taiwan.
Yu ML; Dai CY; Lin ZY; Lee LP; Hou NJ; Hsieh MY; Chen SC; Hsieh MY; Wang LY; Chang WY; Chuang WL
Liver Int; 2006 Feb; 26(1):73-81. PubMed ID: 16420512
[TBL] [Abstract][Full Text] [Related]
15. Treatment of chronic hepatitis C in patients who failed interferon monotherapy: effects of higher doses of interferon and ribavirin combination therapy. The Virginia Cooperative Hepatitis Treatment Group.
Shiffman ML; Hofmann CM; Gabbay J; Luketic VA; Sterling RK; Sanyal AJ; Contos MJ; Ryan MJ; Yoshida C; Rustgi V
Am J Gastroenterol; 2000 Oct; 95(10):2928-35. PubMed ID: 11051370
[TBL] [Abstract][Full Text] [Related]
16. Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial.
Kowdley KV; Lawitz E; Crespo I; Hassanein T; Davis MN; DeMicco M; Bernstein DE; Afdhal N; Vierling JM; Gordon SC; Anderson JK; Hyland RH; Dvory-Sobol H; An D; Hindes RG; Albanis E; Symonds WT; Berrey MM; Nelson DR; Jacobson IM
Lancet; 2013 Jun; 381(9883):2100-7. PubMed ID: 23499440
[TBL] [Abstract][Full Text] [Related]
17. Effect of combination therapy with ribavirin and high-dose interferon-alpha2b for 24 weeks in chronic hepatitis C.
Abe S; Narita R; Oto T; Tabaru A; Otsuki M
J Gastroenterol Hepatol; 2006 Jan; 21(1 Pt 2):308-12. PubMed ID: 16460492
[TBL] [Abstract][Full Text] [Related]
18. Safety and Efficacy of Combined Treatment with Pegylated Interferon Alpha-2b and Ribavirin for HCV Genotype 4 in Children.
El-Karaksy HM; Mogahed EA; El-Raziky MS; Saleh D; Besheer M; Mubarak S
J Interferon Cytokine Res; 2016 Jan; 36(1):1-8. PubMed ID: 26406390
[TBL] [Abstract][Full Text] [Related]
19. Pegylated interferon plus ribavirin in HIV-infected patients with recurrent hepatitis C after liver transplantation: a prospective cohort study.
Castells L; Rimola A; Manzardo C; Valdivieso A; Montero JL; Barcena R; Abradelo M; Xiol X; Aguilera V; Salcedo M; Rodriguez M; Bernal C; Suarez F; Antela A; Olivares S; Del Campo S; Laguno M; Fernandez JR; de la Rosa G; Agüero F; Perez I; González-García J; Esteban-Mur JI; Miro JM;
J Hepatol; 2015 Jan; 62(1):92-100. PubMed ID: 25127748
[TBL] [Abstract][Full Text] [Related]
20. Pegylated interferon and ribavirin combination therapy for chronic hepatitis C virus infection in patients with Child-Pugh Class A liver cirrhosis.
Syed E; Rahbin N; Weiland O; Carlsson T; Oksanen A; Birk M; Davidsdottir L; Hagen K; Hultcrantz R; Aleman S
Scand J Gastroenterol; 2008; 43(11):1378-86. PubMed ID: 18615358
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
